Forecast

The analysts' average price target is +2,36€ (+112,61%). The median is +2,36€ (+112,61%).

Buy	10
Hold	5
Sell	2

News Go to news feed

Inovio falls about 30% after announcing share offering

Inovio has announced a public offering of 21,052,632 common shares plus accompanying warrants at a combined price of $0.95 per share/warrant, after which the stock fell about 30.8% in premarket trading. The warrants have an exercise price of $1.10, and the bookrunner was granted a 30‑day option for up to 3,157,894 additional shares and related warrants. Gross proceeds before deductions are expected to be about $20 million, Piper Sandler is acting as sole manager, and closing is expected around July 31, 2026. » More on de.investing.com
Inovio prices public offering of around $20 million

Inovio has priced a registered public offering of 21,052,632 common shares and accompanying warrants (rights to purchase up to 42,105,264 shares) at a combined price of $0.95 per share plus warrant. The warrants have an exercise price of $1.10 per share. The bookrunner was granted a 30-day overallotment option for up to 3,157,894 additional shares and related warrants. Gross proceeds are estimated at about $20 million before discounts, commissions and expenses; the closing is expected on or about July 31, 2026. Piper Sandler is sole manager. » More on de.investing.com
Inovio reports clinical progress with INO-3107 and improves cost discipline

Inovio released Q1 2026 results and reported clinical progress with its candidate INO-3107, which reduced the need for surgeries in patients. The company cut operating expenses by 13%, improved earnings per share and posted a net loss of $19.7 million; liquidity stood at $37.7 million after a $16 million capital raise. Inovio expects an operating net cash burn of about $18 million for Q2 and is targeting key regulatory milestones for INO-3107, including a possible FDA decision by October 2026; the stock rose 2.84% in after-hours trading. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2017, INOVIO Pharmaceuticals has already paid 0,0601€ in dividends. The last payout was in July 2017.

Financials

In the last quarter, INOVIO Pharmaceuticals had revenue of 0,00€ and net profit of −5,27 Mio€

(EUR)	Jun 2026	YoY
Revenue	0,00	-
Gross profit	0,00	100,00%
Net profit	−5,27 Mio	73,60%
EBITDA	−4,99 Mio	74,20%

Fundamentals

Metric	Value
Market capitalization	+77,15 Mio€
Number of shares	69,09 Mio
52-week high/low	+2,56€ - +0,48€
Dividends	No
Beta	1,51
P/E ratio	−1,12
PEG ratio	0,00
P/B ratio	+24,27
P/S ratio	0,00

Company profile

Inovio Pharmaceuticals, Inc. ist ein Biotechnologieunternehmen, das sich auf die Entdeckung, Entwicklung und Vermarktung von DNA-Medikamenten zur Behandlung und zum Schutz von Menschen vor Krankheiten im Zusammenhang mit dem menschlichen Papillomavirus (HPV), Krebs und Infektionskrankheiten konzentriert. Seine Plattform für DNA-Medikamente verwendet präzise entworfene SynCon, die die DNA-Sequenz des Zielantigens identifizieren und optimieren, sowie die CELLECTRA-Technologie für intelligente Geräte, die die Bereitstellung der DNA-Plasmide erleichtert. Das Unternehmen beschäftigt sich mit der Durchführung und Planung klinischer Studien seiner DNA-Medikamente für HPV-assoziierte Krebsvorstufen, einschließlich Gebärmutterhals-, Vulva- und Analdysplasie; HPV-assoziierte Krebsarten, wie Kopf- und Halskrebs, Gebärmutterhals-, Anal-, Penis-, Vulva- und Vaginalkrebs; andere HPV-assoziierte Erkrankungen, einschließlich rezidivierender Papillomatose der Atemwege; Glioblastoma multiforme; Prostatakrebs; HIV; Ebola; Middle East Respiratory Syndrome (MERS); und Lassa-Fieber. Zu den Partnern und Kollaborateuren gehören ApolloBio Corp., AstraZeneca, Beijing Advaccine Biotechnology Co, Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), Department of Defense (DoD), HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, das Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research und The Wistar Institute. Das Unternehmen hat eine Vereinbarung mit Richter-Helm BioLogics GmbH & Co. KG zur Unterstützung des DNA-Impfstoffs INO-4800 für COVID-19 sowie eine Partnerschaft mit dem International Vaccine Institute und dem Seoul National University Hospital. Das Unternehmen wurde 1979 gegründet und hat seinen Hauptsitz in Plymouth Meeting, Pennsylvania.

Name	INOVIO Pharmaceuticals
CEO	Jacqueline E. Shea
Headquarters	Plymouth Meeting, pa USA
Website	inovio.com
Sector	Health Care
Industry	Pharmaceuticals
IPO	12/08/1998
Employees	112